Agios Pharmaceuticals Prices Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 23, 2013-- Agios Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 5,888,888 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Agios. In addition, Agios has granted the underwriters a 30-day option to purchase up to 883,333 additional shares of common stock from Agios at the public offering price, less the underwriting discount. Agios' common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "AGIO" on July 24, 2013.
The offering is expected to close on July 29, 2013, subject to customary closing conditions.
J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company and Leerink Swan are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 23, 2013.
The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204; or Goldman, Sachs, & Co. Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases.
Source: Agios Pharmaceuticals, Inc.